Ulipristal Acetate in Symptomatic Uterine Fibroid

NCT04132349 PHASE4 TERMINATED

This study evaluates the effectiveness and safety of ulipristal acetae (UPA) in women with symptomatic uterine fibroids. Those who fulfilled inclusion/exclusion criteria will be treated UPA at daily dose of 5mg.

Details

Lead sponsor	Mỹ Đức Hospital
Phase	PHASE4
Status	TERMINATED
Enrolment	25
Start date	Wed Oct 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Apr 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Uterine Fibroid
• Heavy Menstrual Bleeding

Interventions

• Ulipristal Acetate 5 mg

Countries

Vietnam